JP2010184948A - 臓器および組織の治療のための薬剤 - Google Patents
臓器および組織の治療のための薬剤Info
- Publication number
- JP2010184948A JP2010184948A JP2010129337A JP2010129337A JP2010184948A JP 2010184948 A JP2010184948 A JP 2010184948A JP 2010129337 A JP2010129337 A JP 2010129337A JP 2010129337 A JP2010129337 A JP 2010129337A JP 2010184948 A JP2010184948 A JP 2010184948A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tissue
- composition
- fragment
- conjugated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Abstract
【解決手段】患者の非腫瘍細胞若しくは非腫瘍組織の機能を除去するか、または該機能に影響を与えるために、活性成分として、非腫瘍細胞若しくは非腫瘍組織により生成されるか、またはそれらに関連するマーカーに特異的に結合する抗体または抗体フラグメントを含んでなる医薬剤であって、前記抗体または抗体フラグメントが治療剤とコンジュゲートしている医薬剤を使用する。
【選択図】なし
Description
(1)膵臓の島細胞が萎縮または著しく縮小している若年性糖尿病、胸腺発育不全または胸腺無発育、上皮小体と胸腺が形成不全性または欠落しているディ−ジョージ(DiGeorge's)症候群等の、形成不全性の、あるいは欠落した組織または臓器。
(2)子宮内膜腺または支質の埋め込みのような異所性組織および臓器。
(3)妊娠後の胎盤組織の遺残と、臓器を外科的に切除した後の臓器の遺残、および(4)外科的に切除した臓器に近接する臓器の状態。
(5)免疫疾患またはリンパ腫患者の脾臓、骨髄移植が必要な患者の骨髄、または特定の免疫疾患におけるある種のT−リンパ球のような病態プロセスに関与している正常細胞等の、他の治療目的のためのある種の正常臓器または組織の切除。
1.活性成分として、非腫瘍細胞若しくは非腫瘍組織により生産されるか、またはそれらに関連するマーカーに特異的に結合する抗体または抗体フラグメントを含んでなる医薬剤であって、前記抗体または抗体フラグメントは治療剤と複合し、前記医薬剤は患者の非腫瘍細胞又は非腫瘍組織の機能を除去するか、または該機能に影響を与える方法に使用するための医薬剤であり、前記医薬剤を患者に投与して、非腫瘍細胞又は非腫瘍組織が除去されるかそれらの機能に影響を与えることを特徴とする医薬剤。
3.非腫瘍細胞又は非腫瘍組織に生産されるか、またはそれらに関連するマーカーが、ホルモンレセプター又は成長因子である実施態様例1に記載の医薬剤。
4.抗体が、Fv、単鎖抗体、Fab、Fab’、F(ab)2フラグメント又は無傷の抗体である実施態様例1に記載の医薬剤。
5.抗体またはフラグメントが、標的細胞又は標的組織に対して少なくとも60%の特異的な免疫反応性を有し、他の抗原に対して35%未満の交差反応性を有する実施態様例1に記載の医薬剤。
9.前記非腫瘍細胞又は非腫瘍組織が、異所性組織である実施態様例1に記載の医薬剤。
10.前記非腫瘍細胞又は非腫瘍組織が、残留組織である実施態様例1に記載の医薬剤。
12.前記非腫瘍細胞又は非腫瘍組織が、骨髄である実施態様例1に記載の医薬剤。
13.前記非腫瘍性細胞又は非腫瘍性組織が、子宮内膜組織である実施態様例1に記載の医薬剤。
14.前記非腫瘍性細胞又は非腫瘍性組織が、正常脾臓組織である実施態様例1に記載の医薬剤。
15.治療剤が、ラジオアイソトープ、薬剤、毒素、非イオン化放射により活性化される蛍光色素、ホルモン、オートクリン及びサイトカインからなる群から選択される細胞毒性剤である実施態様例1に記載の医薬剤。
Claims (12)
- 正常細胞又は組織に関連のある又は正常細胞又は組織により産生されるマーカーに特異的な抗体又は抗体断片を含む医薬であって、正常細胞又は組織の除去が前記正常細胞又は組織の機能に影響することができる医薬。
- 抗体又は抗体断片がコンジュゲートされている請求項1に記載の医薬。
- 抗体又は抗体断片がコンジュゲートされていない請求項1に記載の医薬。
- 抗体又は抗体断片が細胞毒性剤にコンジュゲートされている請求項2に記載の医薬。
- 細胞又は組織が、ストレプトアビジンにコンジュゲートした抗体、アビジン及びビオチンによるコンジュゲートに使用されるビオチン化抗体、二官能性抗体、抗体−ハプテン複合体、又は酵素にコンジュゲートした抗体を含む第1の組成物によりプレターゲッティングされる請求項1〜3のいずれか1項に記載の医薬であって、前記抗体は、前記正常細胞又は組織に関連のある又は前記正常細胞又は組織により産生されるマーカーに特異的に結合する抗体又は抗体断片であり、第1の組成物が標的細胞又は組織に付着した後、第1の組成物の治療剤を活性化する、又は第1の組成物に治療剤を結合させて治療剤を産生する第2の組成物が投与される請求項1〜3のいずれか1項に記載の医薬。
- 正常細胞又は組織が、形成不全、推定される欠損、置換又は異所性のものである請求項1〜3のいずれか1項に記載の医薬。
- 抗体又は抗体断片が、正常細胞又は組織の成長因子のレセプター又はホルモンレセプターである請求項1〜3のいずれか1項に記載の医薬。
- 正常細胞又は組織に関連のある又は正常細胞又は組織により産生される抗原に特異的であり、ストレプトアビジンにコンジュゲートした抗体又は抗体断片、アビジン及びビオチンによるコンジュゲートに使用されるビオチン化抗体又は抗体断片、二官能性抗体又は抗体断片、抗体又は抗体断片とハプテンの複合体、又は酵素にコンジュゲートした抗体又は抗体断片である抗体又は抗体断片である第1の組成物と、
第1の組成物に結合し、細胞毒性剤を運搬する第2の組成物と
を含むキット。 - 正常細胞又は組織に関連のある又は正常細胞又は組織により産生される抗原に特異的であり、ストレプトアビジンにコンジュゲートした抗体又は抗体断片、アビジン及びビオチンによるコンジュゲートに使用されるビオチン化抗体又は抗体断片、二官能性抗体又は抗体断片、抗体又は抗体断片とハプテンの複合体、又は酵素にコンジュゲートした抗体又は抗体断片である抗体又は抗体断片である第1の組成物と、
第1の組成物に結合し、細胞保護剤を運搬する第2の組成物と
を含むキット。 - 薬理学的に許容可能な無菌注射媒体中の、正常細胞又は組織に関連のある又は正常細胞又は組織により産生される抗原に特異的な抗体又は抗体断片を含む、無菌の注射可能な組成物。
- 薬理学的に許容可能な無菌注射媒体中の、細胞毒性剤にコンジュゲートした、正常細胞又は組織に関連のある又は正常細胞又は組織により産生される抗原に特異的な抗体又は抗体断片を含む、無菌の注射可能な組成物。
- 薬理学的に許容可能な無菌注射媒体中の、細胞保護剤にコンジュゲートした、正常細胞又は組織に関連のある又は正常細胞又は組織により産生される抗原に特異的な抗体又は抗体断片を含む、無菌の注射可能な組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/866,789 US5776093A (en) | 1985-07-05 | 1992-04-07 | Method for imaging and treating organs and tissues |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005322919A Division JP2006083183A (ja) | 1992-04-07 | 2005-11-07 | 臓器および組織の治療のための薬剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010184948A true JP2010184948A (ja) | 2010-08-26 |
Family
ID=25348415
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5517575A Pending JPH07508974A (ja) | 1992-04-07 | 1993-04-02 | 臓器および組織の画像化と治療のための方法およびキット |
JP2000000649A Pending JP2000226338A (ja) | 1992-04-07 | 2000-01-06 | 臓器および組織の治療のための薬剤 |
JP2005322919A Pending JP2006083183A (ja) | 1992-04-07 | 2005-11-07 | 臓器および組織の治療のための薬剤 |
JP2010129337A Pending JP2010184948A (ja) | 1992-04-07 | 2010-06-04 | 臓器および組織の治療のための薬剤 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5517575A Pending JPH07508974A (ja) | 1992-04-07 | 1993-04-02 | 臓器および組織の画像化と治療のための方法およびキット |
JP2000000649A Pending JP2000226338A (ja) | 1992-04-07 | 2000-01-06 | 臓器および組織の治療のための薬剤 |
JP2005322919A Pending JP2006083183A (ja) | 1992-04-07 | 2005-11-07 | 臓器および組織の治療のための薬剤 |
Country Status (13)
Country | Link |
---|---|
US (8) | US5776093A (ja) |
EP (4) | EP0637933B1 (ja) |
JP (4) | JPH07508974A (ja) |
AT (3) | ATE441667T1 (ja) |
AU (3) | AU674846B2 (ja) |
CA (1) | CA2133833C (ja) |
DE (3) | DE69334293D1 (ja) |
DK (2) | DK1393750T3 (ja) |
ES (1) | ES2229207T3 (ja) |
HK (1) | HK1062647A1 (ja) |
IL (5) | IL127509A (ja) |
PT (1) | PT637933E (ja) |
WO (1) | WO1993019668A1 (ja) |
Families Citing this family (235)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5482698A (en) * | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
CA2199864C (en) * | 1994-09-16 | 2006-06-20 | Seth A. Foerster | Methods and devices for defining and marking tissue |
US6540994B1 (en) * | 1997-07-18 | 2003-04-01 | I.D.M. Immuno-Designed Molecules | Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions |
US6102904A (en) * | 1995-07-10 | 2000-08-15 | Interventional Technologies, Inc. | Device for injecting fluid into a wall of a blood vessel |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) * | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US20040005645A1 (en) * | 1996-05-30 | 2004-01-08 | The Regents Of The University Of Michigan | Protein markers for esophageal cancer |
US20060003163A1 (en) * | 1996-11-16 | 2006-01-05 | Nanomagnetics Limited | Magnetic fluid |
US6815063B1 (en) | 1996-11-16 | 2004-11-09 | Nanomagnetics, Ltd. | Magnetic fluid |
US6986942B1 (en) | 1996-11-16 | 2006-01-17 | Nanomagnetics Limited | Microwave absorbing structure |
GB2319253A (en) | 1996-11-16 | 1998-05-20 | Eric Leigh Mayes | Composition, for use in a device, comprising a magnetic layer of domain-separated magnetic particles |
US6713173B2 (en) * | 1996-11-16 | 2004-03-30 | Nanomagnetics Limited | Magnetizable device |
US6171856B1 (en) * | 1997-07-30 | 2001-01-09 | Board Of Regents, The University Of Texas System | Methods and compositions relating to no-mediated cytotoxicity |
US6205352B1 (en) | 1997-11-19 | 2001-03-20 | Oncology Innovations, Inc. | Sentinel node identification using non-isotope means |
US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US7405320B2 (en) | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
US7387772B1 (en) * | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
US7833528B2 (en) * | 1998-06-22 | 2010-11-16 | Immunomedics, Inc. | Use of multispecific, non-covalent complexes for targeted delivery of therapeutics |
US6703050B1 (en) * | 1998-09-04 | 2004-03-09 | The Regents Of The University Of Michigan | Methods and compositions for the prevention or treatment of cancer |
KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US6371904B1 (en) | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
EP1642596A3 (en) * | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
US8383081B2 (en) | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
US8119101B2 (en) | 1999-05-10 | 2012-02-21 | The Ohio State University | Anti-CD74 immunoconjugates and methods of use |
US7829064B2 (en) * | 1999-05-10 | 2010-11-09 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods |
DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
DE60031114T2 (de) * | 1999-06-11 | 2007-05-03 | Cytyc Corp., Marlborough | Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes |
US6489312B1 (en) | 1999-06-15 | 2002-12-03 | Medimmune Oncology, Inc. | Pharmaceutical formulations comprising aminoalkyl phosphorothioates |
AU5905400A (en) | 1999-07-14 | 2001-02-05 | Board Of Regents, The University Of Texas System | Methods and compositions for delivery and retention of active agents to lymph nodes |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
HRP990264A2 (en) | 1999-11-02 | 2001-06-30 | Josip Paladino | Neurosurgical endoscopic ultrasonic contact probe |
US6835370B2 (en) * | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
US20050123545A1 (en) * | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
US7897140B2 (en) * | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US7097826B2 (en) * | 1999-12-23 | 2006-08-29 | Health Research, Inc. | Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
US7166719B2 (en) | 2002-06-27 | 2007-01-23 | Health Research, Inc. | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
US6445945B1 (en) | 2000-06-26 | 2002-09-03 | André Arsenault | Non-invasive detection of endothelial dysfunction by blood flow measurement in opposed limbs using tracer injection |
AU2002225959A1 (en) * | 2000-11-09 | 2002-05-21 | Mayo Foundation For Medical Education And Research | Absolute lymphocyte recovery and cancer survival |
US7422733B2 (en) * | 2000-11-29 | 2008-09-09 | Bracco International B.V. | Linkable sialyl Lewis X analogs |
DE60213771T2 (de) * | 2001-03-30 | 2007-08-16 | The University of Massachusetts, Worcester | Morpholinobildgebung und therapie |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20110313230A1 (en) | 2001-05-11 | 2011-12-22 | Terrance Grant Johns | Specific binding proteins and uses thereof |
US7589180B2 (en) * | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20030007974A1 (en) * | 2001-05-30 | 2003-01-09 | Nanus David M. | Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
MXPA03010804A (es) | 2001-06-01 | 2004-11-22 | Cornell Res Foundation Inc | Anticuerpos modificados para antigeno de membrana especifico de la prostata y usos de los mismos. |
US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
EP1395226A4 (en) * | 2001-06-11 | 2005-03-30 | Univ Miami | USE OF RADIOPHARMETHIC COMPLEXES TO IMPROVE TRANSPLANT TOLERANCE |
US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
US7192586B2 (en) | 2001-09-20 | 2007-03-20 | Cornell Research Foundation, Inc. | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen |
US7769432B2 (en) * | 2001-12-10 | 2010-08-03 | Board Of Trustees Of The University Of Arkansas | Minimally invasive diagnosis and treatment for breast cancer |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
NZ533933A (en) * | 2002-01-02 | 2008-06-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of glioma tumor |
US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
CN101914158A (zh) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
ATE477276T1 (de) | 2002-03-01 | 2010-08-15 | Immunomedics Inc | Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen |
WO2003077865A2 (en) * | 2002-03-15 | 2003-09-25 | Baxter International Inc. | Methods and compositions for directing cells to target organs |
US7452535B2 (en) * | 2002-04-12 | 2008-11-18 | Medarex, Inc. | Methods of treatment using CTLA-4 antibodies |
CA2488753A1 (en) * | 2002-06-07 | 2003-12-18 | Immunomedics, Inc. | Neutrophil imaging methods in cyctic fibrosis |
US20030228256A1 (en) * | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
CA2489467C (en) | 2002-06-14 | 2015-02-24 | Immunomedics, Inc. | Humanized monoclonal antibody hpam4 |
AU2003249742A1 (en) * | 2002-07-02 | 2004-01-23 | Health Research, Inc. | Efficient synthesis of pyropheophorbide a and its derivatives |
JP2005538093A (ja) | 2002-07-23 | 2005-12-15 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物 |
AU2003248982B2 (en) | 2002-08-01 | 2009-12-10 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
MXPA05003843A (es) * | 2002-10-10 | 2006-02-17 | Us Dept Veterans Affairs | Deteccion, localizacion y determicnacion de fases de tumores usando linfocitos activados rotulados dirigidos a un epitope especifico. |
WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
WO2004035608A2 (en) * | 2002-10-18 | 2004-04-29 | Abgenix, Inc. | System and method for cleaving antibodies |
US20040136998A1 (en) * | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
US20060173283A1 (en) * | 2002-11-27 | 2006-08-03 | Oskar Axelsson | Method of magnetic resonance imaging |
JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
ES2314272T3 (es) | 2003-01-10 | 2009-03-16 | Millennium Pharmaceuticals, Inc. | Metodos para el diagnostico y el tratamiento del cancer. |
CA2514277C (en) | 2003-01-31 | 2015-01-20 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
US20040156846A1 (en) * | 2003-02-06 | 2004-08-12 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles using L6 antibodies |
JP2007525434A (ja) | 2003-03-19 | 2007-09-06 | アブジェニックス インコーポレイテッド | T細胞、免疫グロブリンドメインおよびムチンドメイン1(tim−1)抗原に対する抗体およびその使用。 |
US7172751B2 (en) * | 2003-06-13 | 2007-02-06 | Immunomedics, Inc. | D-amino acid peptides |
US7057100B2 (en) * | 2003-06-26 | 2006-06-06 | The J.C. Robinson Seed Co. | Inbred corn line W23129 |
AU2004260936B2 (en) * | 2003-06-27 | 2010-06-10 | Amgen Fremont Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
CA2533878A1 (en) * | 2003-07-29 | 2005-09-22 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
EP1651663B1 (en) * | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
WO2005026325A2 (en) * | 2003-09-10 | 2005-03-24 | Surromed, Inc, | Bivalent targeting of cell surfaces |
WO2005070456A2 (en) * | 2004-01-09 | 2005-08-04 | Millennium Pharmaceuticals, Inc. | Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies |
US20110171126A1 (en) * | 2010-01-11 | 2011-07-14 | Center For Molecular Medicine And Immunology | Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma |
US9550838B2 (en) | 2004-02-13 | 2017-01-24 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
EP1610818A4 (en) * | 2004-03-03 | 2007-09-19 | Millennium Pharm Inc | MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF |
WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
CA2577620A1 (en) * | 2004-08-20 | 2006-02-23 | Dennis Hardy O'dowd | Method of detecting and treating allogenic cells responsible for endometriosis |
JP2008521411A (ja) | 2004-11-30 | 2008-06-26 | キュラジェン コーポレイション | Gpnmbに対する抗体およびその使用 |
WO2006068975A2 (en) | 2004-12-20 | 2006-06-29 | Abgenix, Inc. | Binding proteins specific for human matriptase |
US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
JP5214252B2 (ja) | 2005-03-03 | 2013-06-19 | イミューノメディクス、インコーポレイテッド | ヒト化l243抗体 |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
WO2006099175A2 (en) * | 2005-03-11 | 2006-09-21 | Euro-Celtique S.A. | Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer |
WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
EA015584B1 (ru) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
WO2006104677A2 (en) | 2005-03-24 | 2006-10-05 | Millennium Pharmaceuticals, Inc. | Antibodies that bind ov064 and methods of use therefor |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
CA2615460A1 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
NZ568016A (en) | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
EP2674440B1 (en) | 2005-12-16 | 2019-07-03 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
KR20090029184A (ko) * | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
US9277295B2 (en) * | 2006-06-16 | 2016-03-01 | Cisco Technology, Inc. | Securing media content using interchangeable encryption key |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
WO2008091701A2 (en) | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
WO2008115404A1 (en) | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
CA2696360C (en) * | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
JP2010538798A (ja) * | 2007-09-19 | 2010-12-16 | オンコフルーア インコーポレイテッド | 臓器および組織を撮像および処置するための方法 |
WO2015164330A1 (en) | 2014-04-21 | 2015-10-29 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
EP2090322A1 (en) * | 2008-02-18 | 2009-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fsh receptor ligands for diagnosis and therapy of cancer |
EA201100228A1 (ru) * | 2008-07-21 | 2011-08-30 | Иммьюномедикс, Инк. | Структурные варианты антител для улучшения терапевтических характеристик |
CA2735900A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies directed to dll4 and uses thereof |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
WO2010093450A2 (en) | 2009-02-11 | 2010-08-19 | Ludwing Institute For Cancer Research Ltd. | Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis |
EP2396036B1 (en) | 2009-02-13 | 2017-06-28 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
US20110076232A1 (en) | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US8999342B2 (en) | 2009-10-02 | 2015-04-07 | Ludwig Institute For Cancer Research, Ltd. | Anti-fibroblast activation protein antibodies and methods and uses thereof |
WO2011040973A2 (en) | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd. | Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof |
TWI483736B (zh) | 2009-10-23 | 2015-05-11 | Millennium Pharm Inc | 抗-gcc抗體分子及其相關之組合物及方法 |
US8565892B2 (en) | 2009-10-31 | 2013-10-22 | Qteris, Inc. | Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
RS56469B1 (sr) | 2009-11-24 | 2018-01-31 | Medimmune Ltd | Ciljano vezujući agensi usmereni na b7-h1 |
CA2782194C (en) | 2009-12-02 | 2018-01-16 | Immunomedics, Inc. | Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer |
JP2013534515A (ja) | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体 |
WO2011154453A1 (en) | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
SI2582728T1 (en) | 2010-06-15 | 2018-01-31 | Genmab A/S | Human Antibodies Conjugates against a Tissue Factor |
AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
US20130280167A1 (en) | 2010-10-19 | 2013-10-24 | Moses Rodriguez | Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease |
WO2012061129A1 (en) | 2010-10-25 | 2012-05-10 | Genentech, Inc | Treatment of gastrointestinal inflammation and psoriasis a |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
WO2012099871A1 (en) | 2011-01-17 | 2012-07-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulation of lrch4 activity and therapeutic application thereof |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
CA2832387A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
AP2014007638A0 (en) | 2011-11-16 | 2014-05-31 | Amgen Inc | Methods of treating epidermal growth factor deletion mutant VIII related disorders |
US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS |
CA2863834A1 (en) | 2012-02-06 | 2013-08-15 | Inhibrx Llc | Cd47 antibodies and methods of use thereof |
US20150104460A1 (en) | 2012-04-17 | 2015-04-16 | Mayo Foundation For Medical Education And Research | Human Antibodies and Specific Binding Sequences Thereof for use in Stroke and Ischemia or Ischemic Conditions |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
EP2861259A1 (en) | 2012-06-14 | 2015-04-22 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
SG10201605703TA (en) | 2012-07-06 | 2016-09-29 | Genmab Bv | Dimeric protein with triple mutations |
WO2014028560A2 (en) | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
US9107960B2 (en) | 2012-12-13 | 2015-08-18 | Immunimedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
KR102356017B1 (ko) | 2012-12-13 | 2022-01-27 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
KR20200134340A (ko) | 2013-01-10 | 2020-12-01 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
CA2900468A1 (en) | 2013-02-06 | 2014-08-14 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
CN105026423A (zh) | 2013-03-14 | 2015-11-04 | 瑞泽恩制药公司 | 爱帕琳融合蛋白和其用途 |
KR102207859B1 (ko) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | 고 친화도 항-gd2 항체 |
EP3016681B1 (en) | 2013-07-05 | 2019-12-18 | Genmab A/S | Humanized or chimeric cd3 antibodies |
US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
WO2015023851A1 (en) | 2013-08-14 | 2015-02-19 | The Governing Council Of The University Of Toronto | Antibodies against frizzled proteins and methods of use thereof |
CN106132436B (zh) | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
EP3110445A4 (en) | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
US9580495B2 (en) | 2014-06-24 | 2017-02-28 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
EP3166688A4 (en) | 2014-07-08 | 2017-12-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
PT3169706T (pt) | 2014-07-11 | 2020-03-13 | Genmab As | Anticorpos que se ligam a axl |
EP3954373A1 (en) | 2014-10-07 | 2022-02-16 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
US11180543B2 (en) | 2014-11-07 | 2021-11-23 | Mayo Foundation For Medical Education And Research | Treatment of neonatal hypoxia including impairments or effects thereof |
JP6701217B2 (ja) | 2014-11-25 | 2020-05-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 生物学的製剤の18f−放射性標識方法および組成物 |
CN107580500B (zh) | 2015-02-19 | 2023-05-30 | 康姆普根有限公司 | 抗pvrig抗体和使用方法 |
KR102618312B1 (ko) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항muc16 항체 및 그의 용도 |
WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
US10723793B2 (en) | 2015-06-12 | 2020-07-28 | Ludwig Institute For Cancer Research, Ltd. | TGF-β3 specific antibodies and methods and uses thereof |
US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
CA2983597A1 (en) | 2015-06-25 | 2016-12-29 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
EP3319993B1 (en) | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
US20180305451A1 (en) | 2015-07-13 | 2018-10-25 | Compugen Ltd. | Hide1 compositions and methods |
WO2017027691A1 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
US10988528B2 (en) | 2015-08-13 | 2021-04-27 | New York University | Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
US10335608B2 (en) | 2016-04-20 | 2019-07-02 | Theralase Technologies, Inc. | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics |
JP7379795B2 (ja) | 2016-04-27 | 2023-11-15 | イミューノメディクス、インコーポレイテッド | チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果 |
AU2017268291B2 (en) | 2016-05-19 | 2022-09-29 | Bristol-Myers Squibb Company | PET-imaging immunomodulators |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
KR102551971B1 (ko) | 2016-07-12 | 2023-07-07 | 하. 룬드벡 아크티에셀스카브 | 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 |
MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
CA3041988A1 (en) | 2016-11-01 | 2018-05-11 | Genmab B.V. | Polypeptide variants and uses thereof |
MA47019A (fr) | 2016-12-16 | 2021-04-21 | H Lundbeck As | Agents, utilisations et procédés |
JP7217710B2 (ja) | 2017-01-04 | 2023-02-03 | ハー・ルンドベック・アクチエゼルスカベット | 眼疾患の治療のための過リン酸化タウに特異的な抗体 |
EP3574012A1 (en) | 2017-01-27 | 2019-12-04 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
EP3600283A4 (en) | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
US10799597B2 (en) | 2017-04-03 | 2020-10-13 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
US20210107988A1 (en) | 2018-01-24 | 2021-04-15 | Genmab B.V. | Polypeptide variants and uses thereof |
CA3106146A1 (en) | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
AU2019375036A1 (en) | 2018-11-05 | 2021-06-03 | Centre Hospitalier Universitaire Vaudois | Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof |
WO2020095104A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | HUMANIZED AND VARIANT TGF-β3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
EP3880714A4 (en) | 2018-11-16 | 2022-07-20 | Memorial Sloan Kettering Cancer Center | ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF |
EP3958908A1 (en) | 2019-04-24 | 2022-03-02 | Heidelberg Pharma Research GmbH | Amatoxin antibody-drug conjugates and uses thereof |
CN114599675A (zh) | 2019-05-28 | 2022-06-07 | 上海科技大学 | 用于治疗clouston型外胚层发育不良2的组合物和方法 |
IL294342A (en) | 2020-01-10 | 2022-08-01 | Kling Biotherapeutics B V | Antibodies specific for epithelial cadherin |
EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
WO2021259227A1 (zh) | 2020-06-23 | 2021-12-30 | 江苏康缘药业股份有限公司 | 抗cd38抗体及其用途 |
WO2022189667A1 (en) | 2021-03-12 | 2022-09-15 | Genmab A/S | Non-activating antibody variants |
WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3683066A (en) | 1969-01-14 | 1972-08-08 | Ivan Ascanio | Technetium 99m colloidal composition |
US3683006A (en) * | 1970-09-09 | 1972-08-08 | Syntex Corp | Cyclodecapentaene compounds |
US3927193A (en) * | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
US4087156A (en) * | 1975-11-07 | 1978-05-02 | International Telephone & Telegraph Corporation | Optical fiber transmission mixer and method of making same |
GB1535847A (en) * | 1976-03-19 | 1978-12-13 | Radiochemical Centre Ltd | Technetium-99m labelled tin colloid for body scanning |
US4036945A (en) * | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4234561A (en) * | 1978-02-06 | 1980-11-18 | Research Corporation | Antigen for early pregnancy test and contraceptive vaccine |
US4381295A (en) * | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
US4311688A (en) * | 1979-10-29 | 1982-01-19 | Serono Laboratories Inc. | Composition and method for cancer detection in humans |
US4460561A (en) * | 1980-03-03 | 1984-07-17 | Goldenberg M David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4444744A (en) * | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4348376A (en) * | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4361544A (en) * | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
DE3173342D1 (en) | 1980-03-03 | 1986-02-13 | Milton David Goldenberg | Agent for tumor localization and therapy with labeled antibodies and antibody fragments |
US4440747A (en) * | 1980-09-30 | 1984-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease |
US4468457A (en) * | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
US4489710A (en) * | 1981-06-23 | 1984-12-25 | Xoma Corporation | Composition and method for transplantation therapy |
DE3129906C3 (de) | 1981-07-24 | 1996-12-19 | Schering Ag | Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik |
US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
US4434156A (en) * | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
US5286647A (en) * | 1982-05-21 | 1994-02-15 | University Of California | Human-human hybridomas for neoplasms |
JPS58201994A (ja) * | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4443427A (en) * | 1982-06-21 | 1984-04-17 | Sidney Farber Cancer Institute, Inc. | Monoclonal antibody |
DE3237573A1 (de) * | 1982-10-09 | 1984-04-12 | Hoechst Ag, 6230 Frankfurt | Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung |
US4460459A (en) * | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
US4500508A (en) * | 1983-05-03 | 1985-02-19 | The United States Of America As Represented By The United States Department Of Energy | Radionuclide labeled lymphocytes for therapeutic use |
ATE61000T1 (de) | 1983-07-29 | 1991-03-15 | Milton David Goldenberg | Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren. |
CA1242643A (en) | 1983-08-12 | 1988-10-04 | Eric T. Fossel | Nmr imaging utilizing chemical shift reagents |
US4732864A (en) * | 1983-10-06 | 1988-03-22 | E. I. Du Pont De Nemours And Company | Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules |
US4620971A (en) * | 1983-12-22 | 1986-11-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Indium-bleomycin complex |
US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
US5144010A (en) * | 1984-08-27 | 1992-09-01 | The Trustees Of Columbia University In The City Of New York | Method of producing monoclonal auto-anti-idiotypic antibodies |
NZ212437A (en) * | 1985-06-17 | 1992-06-25 | Mark Philip Best | Site-directed antibody conjugates, and their preparation |
US5101827A (en) * | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5011684A (en) * | 1985-09-05 | 1991-04-30 | Beth Israel Hospital Association | Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance |
US5336489A (en) * | 1985-09-05 | 1994-08-09 | The Beth Israel Hospital Association | Treatment of allograft rejection with IL-2 receptor-specific cytotoxins |
US5053491A (en) * | 1985-12-13 | 1991-10-01 | Washington University School Of Medicine | Monoclonal antibodies and cell lines for parathyroid tissue-specific antigen |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US5670151A (en) * | 1986-04-28 | 1997-09-23 | Chiron Corporation | Method for controlling hyperproliferative diseases |
US4742000A (en) * | 1986-05-02 | 1988-05-03 | University Of Chicago | Antibody to human progesterone receptor and diagnostic materials and methods |
US4857637A (en) * | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
US5182368A (en) * | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
US5478576A (en) * | 1986-07-03 | 1995-12-26 | Advanced Magnetics, Inc. | Arabinogalactan derivatives and uses thereof |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4946675A (en) | 1987-05-27 | 1990-08-07 | Xoma Corporation | Hepatic blocking agents |
ATE137119T1 (de) * | 1987-08-17 | 1996-05-15 | Us Commerce | Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen |
WO1989001629A1 (en) * | 1987-08-19 | 1989-02-23 | Centocor, Inc. | Human ovarian tumor-associated antigen specific for monoclonal antibody ov-tl3 |
US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
US5208021A (en) * | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
US5091313A (en) * | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
ATE136901T1 (de) * | 1988-02-18 | 1996-05-15 | Ks Biomedix Ltd | Antigen gegen diabetes |
US5112954A (en) * | 1988-02-26 | 1992-05-12 | Neorx Corporation | Method of enhancing the effect of cytotoxic agents |
US5011689A (en) * | 1988-03-17 | 1991-04-30 | T. Paul Misenko | Composition of matter and method for treating poison ivy |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
CA1329119C (en) * | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
EP0407462A4 (en) * | 1988-03-30 | 1992-02-05 | Arch Development Corporation | Dna binding proteins including androgen receptor |
GB8808015D0 (en) * | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
US5152980A (en) * | 1988-05-19 | 1992-10-06 | The Beth Israel Hospital Association | Induction of tolerance to a foreign antigen IL-2 receptor-binding substances |
US5006652A (en) | 1988-08-08 | 1991-04-09 | Eli Lilly And Company | Intermediates for antibody-vinca drug conjugates |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5144007A (en) * | 1988-11-03 | 1992-09-01 | La Jolla Cancer Research Foundation | Thyroid hormone receptor |
US5223426A (en) * | 1988-12-15 | 1993-06-29 | T Cell Sciences, Inc. | Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor |
GB2228262B (en) * | 1989-01-25 | 1992-10-07 | Nat Inst Immunology | Antigenic derivative of gnrh |
EP0485476A4 (en) | 1989-07-31 | 1993-03-03 | Vasocor | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
DK0493446T3 (da) * | 1989-09-15 | 1997-08-11 | Tanox Biosystems Inc | Behandling af autoimmunsygdom. |
CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2072017A1 (en) | 1989-12-14 | 1991-06-15 | David A. Scheinberg | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
AU7566991A (en) * | 1990-03-14 | 1991-10-10 | Biomembrane Institute, The | Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders |
WO1991016069A1 (en) * | 1990-04-17 | 1991-10-31 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Selective cytotoxic reagents comprising toxic moieties derived from mammalian proteins |
US5223241A (en) * | 1990-10-01 | 1993-06-29 | The General Hospital Corporation | Method for early detection of allograft rejection |
US5322699A (en) * | 1991-02-04 | 1994-06-21 | The Rockefeller University | Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1) |
WO1992014493A1 (en) * | 1991-02-20 | 1992-09-03 | Christopher Capelli | Non-protein intracellular receptor binding conjugates and a method of use thereof |
US5326559A (en) * | 1991-05-16 | 1994-07-05 | Miller D Douglas | Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules |
US5298499A (en) * | 1991-07-05 | 1994-03-29 | Research Triangle Institute | S-2-(substituted ethylamino)ethyl phosphorothioates |
US5225182A (en) * | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
ATE348110T1 (de) * | 1992-10-28 | 2007-01-15 | Genentech Inc | Hvegf rezeptor als vegf antagonist |
US5482698A (en) * | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
US5411985A (en) * | 1993-05-17 | 1995-05-02 | Merck & Co., Inc. | Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US6653104B2 (en) * | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
DE60042785D1 (de) * | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
CN101914158A (zh) * | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
-
1992
- 1992-04-07 US US07/866,789 patent/US5776093A/en not_active Expired - Lifetime
-
1993
- 1993-04-02 CA CA002133833A patent/CA2133833C/en not_active Expired - Lifetime
- 1993-04-02 AU AU39370/93A patent/AU674846B2/en not_active Expired
- 1993-04-02 DE DE69334293T patent/DE69334293D1/de not_active Expired - Lifetime
- 1993-04-02 EP EP93908607A patent/EP0637933B1/en not_active Revoked
- 1993-04-02 DK DK03078022T patent/DK1393750T3/da active
- 1993-04-02 ES ES93908607T patent/ES2229207T3/es not_active Expired - Lifetime
- 1993-04-02 EP EP03078022A patent/EP1393750B1/en not_active Expired - Lifetime
- 1993-04-02 WO PCT/US1993/002848 patent/WO1993019668A1/en active IP Right Grant
- 1993-04-02 JP JP5517575A patent/JPH07508974A/ja active Pending
- 1993-04-02 DK DK93908607T patent/DK0637933T3/da active
- 1993-04-02 AT AT03078022T patent/ATE441667T1/de not_active IP Right Cessation
- 1993-04-02 AT AT93908607T patent/ATE279215T1/de not_active IP Right Cessation
- 1993-04-02 PT PT93908607T patent/PT637933E/pt unknown
- 1993-04-02 DE DE69334294T patent/DE69334294D1/de not_active Expired - Lifetime
- 1993-04-02 EP EP03076876A patent/EP1375519A3/en not_active Ceased
- 1993-04-02 DE DE69333658T patent/DE69333658T2/de not_active Expired - Lifetime
- 1993-04-02 AT AT03076875T patent/ATE441438T1/de not_active IP Right Cessation
- 1993-04-02 EP EP03076875A patent/EP1384488B1/en not_active Expired - Lifetime
- 1993-04-04 IL IL12750993A patent/IL127509A/xx not_active IP Right Cessation
- 1993-04-04 IL IL10530293A patent/IL105302A/en not_active IP Right Cessation
- 1993-04-04 IL IL12751093A patent/IL127510A/xx not_active IP Right Cessation
-
1995
- 1995-06-01 US US08/456,629 patent/US5776094A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,909 patent/US5697902A/en not_active Expired - Lifetime
- 1995-06-01 US US08/456,914 patent/US5776095A/en not_active Expired - Lifetime
-
1996
- 1996-07-12 AU AU59460/96A patent/AU5946096A/en not_active Abandoned
-
1998
- 1998-07-06 US US09/110,181 patent/US6331175B1/en not_active Expired - Fee Related
- 1998-12-10 IL IL12750998A patent/IL127509A0/xx unknown
- 1998-12-10 IL IL12751098A patent/IL127510A0/xx unknown
-
1999
- 1999-01-14 AU AU11318/99A patent/AU1131899A/en not_active Abandoned
-
2000
- 2000-01-06 JP JP2000000649A patent/JP2000226338A/ja active Pending
-
2001
- 2001-12-05 US US10/002,211 patent/US20020052594A1/en not_active Abandoned
-
2004
- 2004-07-28 HK HK04105584.7A patent/HK1062647A1/xx not_active IP Right Cessation
-
2005
- 2005-09-20 US US11/229,872 patent/US7811570B2/en not_active Expired - Fee Related
- 2005-11-07 JP JP2005322919A patent/JP2006083183A/ja active Pending
-
2010
- 2010-06-04 JP JP2010129337A patent/JP2010184948A/ja active Pending
-
2011
- 2011-01-10 US US12/987,814 patent/US20110117105A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6331175B1 (en) | Method and kit for imaging and treating organs and tissues | |
US5101827A (en) | Lymphographic and organ imaging method and kit | |
US4735210A (en) | Lymphographic and organ imaging method and kit | |
Goldenberg et al. | History and status of tumor imaging with radiolabeled antibodies | |
JPH08500335A (ja) | 手術,血管内手技または内視鏡手技における腫瘍および病変の検出と治療 | |
EP1169064B1 (en) | Method of detecting endometriosis | |
JPH08510250A (ja) | ビオチンまたはアビジンと金属キレート化タンパク質との複合体による病変の検出および治療法の改善 | |
US20070010014A1 (en) | Compositions and methods for enhanced delivery to target sites | |
JP2002531523A (ja) | プレターゲッティング方法を用いるホウ素中性子捕獲療法 | |
US20060062728A1 (en) | Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using | |
US20070009428A1 (en) | Compounds and methods for enhanced delivery to disease targets | |
US20070009435A1 (en) | Compositions and methods for enhanced delivery to target sites | |
US20070009427A1 (en) | Compounds and methods for enhanced delivery to disease targets | |
Endo et al. | Tumor imaging by monoclonal antibodies labeled with radioactive metal ions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100705 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110318 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110506 |